Osteoporosis News and Research

Latest Osteoporosis News and Research

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) today announced that Dr. Shinya Yamanaka will receive its 26th annual Kyoto Prize in Advanced Technology, which for 2010 focuses on the fields of Biotechnology and Medical Technology. Dr. Yamanaka, 47, will receive the award for his pioneering work in developing a technology to generate pluripotent stem cells that does not require the use of human embryos.

18 Jun 2010

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Two separate studies have shown that vitamin D deficiency is common in patients with a range of rheumatic diseases, with over half of all patients having below the 'normal' healthy levels of vitamin D (48-145 nmol/L) in their bodies. A further study assessing response to vitamin D supplementation found that taking the recommended daily dose did not normalise vitamin D levels in rheumatic disease patients.

18 Jun 2010

Postmenopausal women who have low calcium intake show higher risk of developing osteoporosis, hypertension

Italian postmenopausal women who have a low calcium intake show a higher risk of developing both osteoporosis and hypertension (a chronic medical condition in which arterial blood pressure is elevated) than those who consume higher levels of calcium according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce the incidence and severity of viral respiratory tract infections including influenza, according to a new study conducted by investigators at Greenwich Hospital and Yale University School of Medicine.

16 Jun 2010

Female endurance sports athletes are at risk for serious health issues, say physicians

Female endurance sports athletes may be at risk for serious health issues, according to physicians at Loyola University Health System. Excessive exercise and inadequate nutrition can lead to problems such as low energy, menstrual irregularity, fertility issues, stress fractures and osteoporosis.

15 Jun 2010

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

14 Jun 2010

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

11 Jun 2010

Misinterpretation of genetic information may undermine efforts to promote behavioral changes for disease prevention

Does knowing that genes are partly responsible for your health condition mean you are less likely to be motivated to find out about the benefits of behavioral changes? According to Dr. Suzanne O'Neill from the National Human Genome Research Institute/National Institutes of Health, and her colleagues, people on the whole are still interested in how health habits affect disease risk.

10 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

SciMed Technologies receives certification for VitaKit A from AOAC International

SciMed Technologies Inc. today announces they received certification from the AOAC International - a worldwide scientific association dedicated to analytical excellence - for VitaKit A the world's first 2 hour rapid test for accurate analysis of vitamin A in liquid milk.

8 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

7 Jun 2010

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc. today announced that it has entered into an expanded relationship with Novartis Pharma AG pursuant to which Novartis has cancelled the Company's Convertible Promissory Note. The Note was originally issued to Novartis on December 1, 2004 in connection with the Research Collaboration and Option License Agreement between the parties of that date and was originally due December 1, 2009. Previously, Novartis had agreed to extend the maturity date to June 4, 2010.

4 Jun 2010

Testosterone deficiency can lead to multiple disorders

Almost a quarter of men treated for cancer in their childhood suffer from a deficiency of the male sex hormone testosterone.

3 Jun 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.

3 Jun 2010

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis -- cathepsin K -- eluded reliable detection in laboratory experiments in the past. Now, a research team at the Georgia Institute of Technology has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography.

2 Jun 2010

Medicare patients may face accessibility crisis to medical care

According to an article in the June issue of the Journal of Bone and Joint Surgery (JBJS), Medicare patients - many who suffer from disabling arthritis of the hip and knee, among other age-related ailments - may end up facing an accessibility crisis to medical care.

2 Jun 2010

Over-the-counter supplements can cause hypertension and kidney failure

Negative health effects linked to taking too much supplemental calcium are on the rise, according to a commentary appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

Osteoporosis News and Research

Latest Osteoporosis News and Research

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Postmenopausal women who have low calcium intake show higher risk of developing osteoporosis, hypertension

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Female endurance sports athletes are at risk for serious health issues, say physicians

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Misinterpretation of genetic information may undermine efforts to promote behavioral changes for disease prevention

Some commonly used drugs cause bone loss: New research

SciMed Technologies receives certification for VitaKit A from AOAC International

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Testosterone deficiency can lead to multiple disorders

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

Medicare patients may face accessibility crisis to medical care

Over-the-counter supplements can cause hypertension and kidney failure

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

FDA approves Prolia for postmenopausal women with osteoporosis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Osteoporosis News and Research

Latest Osteoporosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in